Video

Treatment Decisions in Non–Small Cell Lung Cancer

This publication highlights insights from expert stakeholders on the evolving therapeutic landscape of immunotherapy-based treatment regimens through a review of clinical scenarios of patients with non-small cell lung cancer.

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Related Content
Helen J. Ross, MD, of RUSH Cancer Center
July 25th 2024

Atezolizumab Before and After CRT Appears Safe, Effective in Unresectable Stage III NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Barbara Melosky, MD, FRCPC
July 12th 2024

Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, of Winship Cancer Institute
July 12th 2024

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes